UPDATE : Wednesday, January 22, 2020
Embryonic Stem Cell Technology Developed by Yonsei University Transfers to S.BIOMEDICSThe technology initiated by Prof. Kim Dong-wook will be applied to spinal damage and Parkinson’s syndrome etc.
  • By Lee Hye-seon
  • Published 2017.01.18 12:06
  • Updated 2017.02.20 17:07
  • comments 0

Yonsei university-industry foundation said that it transferred the patent right about ‘Neural precursors from human embryonic stem cells for curing CNS defect’ to the cell therapy product company, S.BIOMEDICS(CEO Kang Dong-ho).

The technology was initiated by Prof. Kim Dong-wook at Yonsei University. And it is based on the result that transplanting cells which aren’t turned into malignant tumors at the neural precursor cell stage during embryonic stem cell differentiation is possible.

specially the characteristic of the technology is to divide all kinds of embryonic stem cells to neuro cells by blocking the signal to restrain the division processes of embryonic stem cells to neuro cells.

The technology was selected as the international standard technology in ‘International Stem Cell Initiative (ISCI)’ under the international stem cell forum held in England in 2010. The result appeared in the official journal of international stem cell society, ‘Stem Cell Reports’.

S.BIOMEDICS plans to apply the technology to patients with spinal damage and Parkinson’s syndrome etc.

Tests for animals are underway to commercialize the treatment for spinal damage. Its goal is to conduct clinical trials within this year and also perform clinical trials to develop the treatment for Parkinson’s syndrome in 2018.

CEO Kang Dong-ho said “currently, we are researching and developing the treatments for Parkinson’s disease and spinal damage using embryonic stem cells in cooperation with the research team driven by Prof. Dongwook Kim. The treatment for spinal damage using embryonic stem cells will be the first trial and the treatment for Parkinson’s disease will be the third in the world. Because the technology is outstanding cell treatment, we will finish clinical trials at an early stage in Korea as soon as possible and plan to do clinical trials at the global level.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Hye-seon
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top